PRODUCTION OF GLUTAMIC ACID DECARBOXYLASE AND ASSOCIATED POLYPEPTIDES FOR USE IN CLINICAL AND RESEARCH APPLICATIONS
UCLA Technology Available For Licensing

The vast majority of Type 1 diabetes (T1D) patients have sera which contain auto-antibodies and T cells reactive to glutamic acid decarboxylase (GAD) and/or peptide fragments of GAD. The present UCLA invention involves the cloning and production of GAD polypeptides for use in detection of autoantibodies and T cells reactive to GAD in biological samples. This method, therefore, may be developed into antibody and T cell-based diagnostic kits for identifying individuals at risk of developing T1D and to distinguish late onset T1D patients from Type II diabetes patients. Furthermore, the invention may also be used for purposes of screening drugs, such as those that alter GAD function, and for generation of polyclonal and monoclonal antibodies which, in turn, can be used diagnostically to detect GAD. Please see http://www.research.ucla.edu/tech/ucla97-561.htm for diagnostic and therapeutic strategies for IDDM based on TH1 and TH2 responses.

Reference: UCLA Case No. 1990-555 US Patent Numbers: 6,277,586 | 5,475,086 | 5,705,626
Related Patents on GAD's Applications:
5,674,978 | 6,011,139 | 5,846,740 | 6,455,267 | 5,998,366 | 6,207,159 | 6,022,697

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
NCD URL:   http://www.research.ucla.edu/tech/ucla90-555.htm

Lead Inventor: Daniel Kaufman

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/tech

Copyright © 2002 The Regents of the University of California.

keywords: therapeutics biological reagents tool uclancd ucla technologies intellectual property patents technology transfer invention business card